As the ctDNA cancer monitoring market becomes increasingly competitive, established panels continue to maintain their foothold amidst a surge of new entrants. Purdie Pascoe is conducting an ongoing syndicated study exploring the US ctDNA Cancer Monitoring Landscape. Waves 1 through 3 are available for immediate purchase, with Wave 4 launching soon.

Experts presenters from across the industry; Breda Kearny - Clinical Regulatory Lead, BSI, Diane M. Legere - Senior Clinical Auditor, DNV, Marcus Torr - Head of Post Market Surveys, Purdie Pascoe and Efsthathios Vassiliadis - CEO, Evnia.

In the fast-evolving world of medical technology, innovation alone isn’t enough. A brilliant device or digital therapeutic can fail if it doesn’t align with the needs of end users, clinical workflows, or regulatory pathways. That’s where market research steps in, not as a luxury, but as a strategic necessity.

In the era of personalised medicine, digital therapeutics, and outcome-based healthcare, a molecule alone is no longer enough. Pharma companies must now deliver integrated solutions, combining drugs, devices, and digital tools to truly improve patient outcomes. After all, not everything that makes you better is a pill.

On  2 August 2025, the second phase of the Act came into force, introducing new compliance standards for providers of general-purpose AI models. These updates mark a significant step in ensuring AI systems are not only powerful but also trustworthy. 

As MedTech professionals know, the industry rarely sleeps, but let’s be honest: in August, it definitely takes a nap. With inboxes a little quieter and decision-makers (hopefully) stealing a few hours in the sun, it’s the perfect time for some lighter reflection. So, grab your iced coffee (or something stronger), and let’s talk Post Market Surveys, from the poolside.

Partnering with an external team that understands and supports every stage of the MedTech journey can be transformative. In this conversation, leading experts share how Purdie Pascoe’s integrated expertise in Primary Market Research and Post Market Surveys is the true golden ticket to a seamless, compliant, and impactful approach for success in your MedTech journey.

Find out how we provided our client with a clear and effective path forward to help launch their pre-filled syringes for subcutaneous immunoglobulin therapy, and how best to position themselves for widespread adoption.

In this session, Breda Kearney, Clinical Regulatory Lead from BSI and Chris Webb, Research Manager and PMCF expert from Purdie Pascoe explore the correct application of Article 61(10) under the EU MDR and the critical role of PMCF surveys in supporting compliance.

In a world where many agencies claim to serve MedTech, very few are true specialists. MedTech isn’t just one of our sectors - it’s our sole focus. That’s what sets us apart. We’re proudly returning to our roots and doubling down on what we do best; helping companies like yours make smarter, faster, and more confident decisions.

Harry Thomas is our dedicated Data Quality Assurance Officer at Purdie Pascoe. In this interview, Harry shares insights about his role and key processes from handling discrepancies or anomalies in collected data to how to adapt when working with new or evolving data collection technologies.

Stephen Potts, Director at Purdie Pascoe, was recently interviewed by Rohit Sahgal, Chief Editor and AI Strategist at TVP Singapore, for the first episode of the 6th season of the Voices Project Asia Podcast. They delve into a range of topics such the importance of relationships in Asia, innovation, finding a ‘killer insight’, navigating the era of ‘info-besity’, rare diseases and the growing role of AI in healthcare.

Paolo Gambetti, Head of Innovation, recently attended the IIEX Europe Innovation conference in Amsterdam. In this blog, he summarises his key takeaways from AI-moderated interviews, smarter visual and behavioural testing, data quality and efficiency and thinking outside the (AI) box.

Our client’s device is used for a specific indication, however users identified a potential benefit of the device’s design to perform for another indication. This study differs from typical PMCF efforts, with an aim to update the device’s labelling (IFUs) with safety and feasibility data for the expanded use. Find out how we heled out client in collecting retrospective real-world data to support the indication expansion.

Primary market research for precision medicine and diagnostics is complex, yet essential. The landscape is shaped by rapid advancements in genomic and proteomic sciences, the increased complexity of treatment algorithm and the need for early detection and personalised treatment plans. These factors create a dynamic environment where understanding market trends, customer needs and the competitive landscape is crucial for success.

As we navigate through the busy conference season, the industry is buzzing with innovation, networking, and knowledge sharing. Conferences are pivotal events that drive advancements, offering a unique platform for professionals to stay ahead of the curve. However, the true value of these events lies in the insights they generate.

Ellie Baker recently joined Purdie Pascoe as PMCF Commercial Director. In this interview, Ellie shares why medical device manufacturers consider PMCF surveys, how she helps guide clients through the complexities of the MedTech landscape and how her first few weeks have been at the business.

Post-Market Clinical Follow-up (PMCF) surveys can help address clinical data gaps that may impact the ongoing assessment of a medical device’s safety and performance. Unearthing clinical gaps requires a systematic approach, including a review of clinical literature, post-market surveillance data, and regulatory compliance standards.

When visiting a sensitive, emotive topic as a means to creating or refining a communications strategy, how can you optimise the true value of the voice of your customer? In this article, Sabera Hyderally and Hazel Haskayne showcase the true value of the Delphi Method and how it can be used in market research as a powerful tool for reaching consensus.

We are delighted to be attending and presenting a paper at the EphMRA Conference from 24-26 June in London. Directors Stephen Potts and Hazel Haskayne will be representing Purdie Pascoe at the event and are excited to meet fellow industry experts and delve into the latest intelligent thinking which is truly making a difference in healthcare market research worldwide.